Af­ter lin­ing up a cou­ple of big bio­phar­ma col­lab­o­ra­tions with large up­front pay­ments in 2017, Cy­tomX $CT­MX is get­ting this year start­ed by bid­ding one of its first Big Phar­ma part­ners so long.

Sean Mc­Carthy,Cy­tomX CEO

The South San Fran­cis­co-based biotech says that Pfiz­er $PFE no­ti­fied them yes­ter­day that they are drop­ping out of the Pro­body deal, dis­card­ing its lat­est two tar­gets af­ter dump­ing the first on EGFR and nev­er go­ing af­ter the fourth. The deal, which start­ed out with a $25 mil­lion up­front pay­ment and a large $610 mil­lion pack­age of mile­stones, had helped val­i­date Cy­tomX’s plat­form tech on armed an­ti­bod­ies. Pfiz­er was look­ing for safer ver­sions of Er­bitux and Vectibix.

Cy­tomX scored $60 mil­lion in up­front cash when Am­gen signed up for a $1.5 bil­lion deal last fall. And that came af­ter Bris­tol-My­ers Squibb forked over $200 mil­lion in cash to get the biotech fo­cused on a safer, bet­ter CT­LA-4 to even­tu­al­ly suc­ceed Yer­voy.

Am­gen $AMGN jumped in for a T-cell en­gag­ing bis­pe­cif­ic tar­get­ing the Epi­der­mal Growth Fac­tor Re­cep­tor (EGFR), a high-val­ue tar­get ex­pressed on mul­ti­ple can­cer types. They’re build­ing on the biotech’s pre­clin­i­cal work on an EGFRx­CD3 pro­gram.

Almost 10 years have passed since its first FDA approval and Regeneron’s macular degeneration injection Eylea continues to pile up sales to the tune of about $5 billion per year, or more than half of Regeneron’s annual revenues.

Those billions are not expected to go anywhere anytime soon thanks to competition, even as Novartis subsidiary Sandoz announced Monday that it’s beginning a Phase III trial for an Eylea biosimilar in 460 patients across 20 countries.

Eli Lilly was one of the earliest players in the race for a Covid-19 antibody, but a series of setbacks at a New Jersey manufacturing site have set back its efforts. Now, an internal complaint reportedly claims that a director at that site knowingly fudged quality control docs right under the FDA’s nose.

An employee complaint from Eli Lilly’s manufacturing plant in Branchburg, NJ, alleged that a director altered documents handed over to FDA regulators as part of an effort to downplay serious quality control issues amid the agency’s probe at the site, Reuters reported.